Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01402544 · ClinicalTrials.gov registry record · Phase 2
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
A Phase 2 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01402544 is a Phase 2 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 20 participants.
The verdict
NCT01402544, a Phase 2 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.
Interventions
- DRUG ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01402544
The ClinicalTrials.gov registry entry for NCT01402544 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ranibizumab is the first listed.
NCT01402544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01402544 about?
NCT01402544 is a clinical study titled "Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab". To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.
What is the current status of trial NCT01402544?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-07. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01402544?
The interventions under investigation include: ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01402544?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.